C.M. Bidwell & Associates’s Moderna MRNA Stock Holding History

C.M. Bidwell & Associates’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$232K	Buy	+4,560	New	+$213K	0.11%	124
2023 Q1	–	Sell	-1,108	Closed	-$199K	–	542
2022 Q4	$199K	Sell	1,108 -351	-24%	-$57.4K	0.16%	125
2022 Q3	$173K	Sell	1,459 -241	-14%	-$36.6K	0.14%	131
2022 Q2	$243K	Buy	+1,700	New	+$243K	0.19%	89
2021 Q4	–	Sell	-739	Closed	-$284K	–	604
2021 Q3	$284K	Sell	739 -606	-45%	-$223K	0.19%	97
2021 Q2	$316K	Sell	1,345 -205	-13%	-$36.6K	0.21%	83
2021 Q1	$203K	Buy	1,550 +736	+90%	+$107K	0.15%	129
2020 Q4	$85K	Buy	+814	New	+$82.3K	0.07%	251

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

C.M. Bidwell & Associates's MRNA Position: Q1 2026 in Review

C.M. Bidwell & Associates opened a new position in Moderna (MRNA) in Q1 2026: 4,560 shares worth $232K. The stake represents 0.11% of the portfolio and ranks #124 among its holdings. This is a return to the name: C.M. Bidwell & Associates previously reported a position in MRNA as recently as Q4 2022.

C.M. Bidwell & Associates first reported a position in MRNA in Q4 2020 and has held it in 8 quarters since. The position peaked at $316K in Q2 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

C.M. Bidwell & Associates held 4,560 shares of Moderna worth $232K as of Q1 2026.
Moderna was a new C.M. Bidwell & Associates position in Q1 2026.
Moderna made up 0.11% of C.M. Bidwell & Associates's portfolio in Q1 2026, its #124 holding.
C.M. Bidwell & Associates first reported a position in Moderna in Q4 2020 and has held it in 8 quarters since.
C.M. Bidwell & Associates's Moderna position peaked at $316K in Q2 2021.
722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2026, filed 15 May 2026.